# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-19-000063
Filing Date
2019-04-24
Accepted
2019-04-23 18:08:58
Documents
10
Period of Report
2019-06-06
Effectiveness Date
2019-04-24

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | lgnd-2019annualmeetingproxy.htm | DEF 14A | 1394997
2 |  | graph.jpg | GRAPHIC | 113635
3 |  | image1a01.gif | GRAPHIC | 565
4 |  | image2.gif | GRAPHIC | 1174
5 |  | image3.gif | GRAPHIC | 612
6 |  | image4.gif | GRAPHIC | 431
7 |  | ligandlogo41719.jpg | GRAPHIC | 12141
8 |  | ligandlogo41719a01.jpg | GRAPHIC | 12141
9 |  | proxycard1of2.jpg | GRAPHIC | 350144
10 |  | proxycard2of2.jpg | GRAPHIC | 225921
| Complete submission text file | 0000886163-19-000063.txt |  | 2362333

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 19762329
SIC: 2834 Pharmaceutical Preparations